<p>切維切斯信託控股公司在最近向證券交易委員會提交的 13F 文件中表示，在第二季度將其在 MaxCyte, Inc.（納斯達克代碼：MXCT - 免費報告）中的股份減少了 22.7%。該機構投資者在此期間出售了 506,943 股後，持有 1,723,239 股該公司的股票。切維切斯信託控股公司在最近的報告期末持有約 1.62% 的 MaxCyte 股份，價值 375.7 萬美元。</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>其他幾家大型投資者最近也增加或減少了對該股票的持股。Mudita Advisors LLP 在第一季度將其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 現在持有 3,328,441 股該公司的股票，價值 908.7 萬美元，此前在上個季度購買了 105,034 股。Gagnon Securities LLC 在第一季度將其在 MaxCyte 的持股增加了 431.3%。Gagnon Securities LLC 現在持有 1,048,318 股該公司的股票，價值 286.2 萬美元，此前在上個季度購買了 850,992 股。Royce &amp; Associates LP 在第一季度將其在 MaxCyte 的持股增加了 30.1%。Royce &amp; Associates LP 現在持有 1,040,873 股該公司的股票，價值 284.2 萬美元，此前在上個季度購買了 241,000 股。Gagnon Advisors LLC 在第一季度獲得了 MaxCyte 的新股份，價值 255 萬美元。最後，Rice Hall James &amp; Associates LLC 在第一季度將其在 MaxCyte 的持股增加了 72.2%。Rice Hall James &amp; Associates LLC 現在持有 454,365 股該公司的股票，價值 124 萬美元，此前在上個季度購買了 190,532 股。目前 68.81% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部買賣</h2>
<p>在其他消息中，首席財務官 Douglas J. Swirsky 在 8 月 13 日星期三購買了 50,000 股該公司的股票。每股平均購買價格為 1.29 美元，總交易額為 64,500.00 美元。購買完成後，首席財務官持有 161,811 股該公司的股票，價值 208,736.19 美元。這筆交易代表了他們持股的 44.72% 的增長。該購買在向證券交易委員會的文件中披露，相關信息可通過 SEC 網站獲取。此外，董事 Stanley C. Erck 在 8 月 13 日星期三購買了 100,000 股該公司的股票。該股票的平均購買價格為 1.37 美元，總交易額為 137,000.00 美元。購買後，該董事直接持有 398,328 股該公司的股票，價值 545,709.36 美元。這筆交易代表了他們持股的 33.52% 的增長。該購買的披露信息可以在這裏找到。內部人士在過去九十天內購買了 355,000 股公司股票，價值 479,950 美元。內部人士持有該公司 3.30% 的股票。</p>
<h2>MaxCyte 股票表現</h2>
<p>納斯達克：MXCT 在星期二開盤價為 1.75 美元。該股票的 50 日簡單移動平均為 1.51 美元，200 日簡單移動平均為 2.02 美元。MaxCyte, Inc.的年低為 1.26 美元，年高為 5.20 美元。該公司的市值為 1.8656 億美元，市盈率為-4.07，貝塔值為 1.23。</p>
<p>MaxCyte（納斯達克：MXCT - 獲取免費報告）最近在 8 月 6 日星期三發佈了其財報。該公司報告季度每股收益（EPS）為（0.12 美元），低於分析師一致預期的（0.10 美元）2 美分。MaxCyte 的股本回報率為-22.12%，淨利潤率為-125.22%。該季度的營業收入為 851 萬美元，而一致預期為 957 萬美元。平均而言，股票研究分析師預測 MaxCyte, Inc.在當前財年將發佈-0.42 的每股收益。</p>
<h2>分析師評級變動</h2>
<p>幾位分析師最近對該公司發佈了報告。華爾街 Zen 在 8 月 9 日星期六將 MaxCyte 的評級從 “持有” 下調至 “賣出”。Stephens 在 7 月 22 日星期二的研究報告中開始覆蓋 MaxCyte 的股票。他們給予了 “增持” 評級，並設定了 6.00 美元的目標價。BTIG Research 在 8 月 11 日星期一的研究報告中重新發布了 MaxCyte 的 “中性” 評級。William Blair 在 8 月 7 日星期四的研究報告中將 MaxCyte 的股票評級從 “跑贏大盤” 下調至 “市場表現”。最後，Weiss Ratings 在 10 月 14 日星期二的研究報告中重新發布了 MaxCyte 的 “賣出（d-）” 評級。兩位研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 7.00 美元。</p>
<p><strong>查看我們對 MaxCyte 的最新股票分析</strong></p>
<h2>關於 MaxCyte</h2>
<p>（免費報告）</p>
<p>MaxCyte, Inc.是一家生命科學公司，在美國和國際上發現、開發和商業化下一代細胞療法。其產品包括 ExPERT ATx，一種用於小到中型規模轉染的靜態電穿孔儀；ExPERT STx，一種用於蛋白質生產和藥物開發的流動電穿孔儀，以及用於細胞基礎檢測的治療靶標表達；ExPERT GTx，一種用於治療應用的大規模轉染的流動電穿孔儀；以及 ExPERT VLx，用於非常大體積的細胞工程。</p>
<h2>推薦閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票勝過 MaxCyte</li>
<li>投資優先股與普通股的比較</li>
<li>路易威登財報顯示奢侈品牛市尚未結束</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>3 家高收益銀行供投資者在下跌時購買</li>
<li>一些最佳的大盤股有哪些？</li>
<li>5 只意外受益於未來機器人熱潮的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 MaxCyte 嗎？</h2>
<p>在你考慮 MaxCyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 MaxCyte 並不在名單上。</p>
<p>雖然 MaxCyte 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MXCT

<p>Chevy Chase Trust Holdings LLC 在第二季度減少了對 MaxCyte, Inc. (NASDAQ:MXCT) 的持股比例，下降了 22.7%，目前持有 1,723,239 股，價值 376 萬美元。其他投資者，包括 Mudita Advisors 和 Gagnon Securities，增加了他們的持股。首席財務官 Douglas J. Swirsky 和董事 Stanley C. Erck 進行了大量股票購買。MaxCyte 的股票開盤價為 1.75 美元，市值為 1.8656 億美元。該公司報告第二季度每股虧損 0.12 美元，未能達到預期，分析師對該股票的評級不一，有些將其下調至 “賣出”</p>

<p>Chevy Chase Trust Holdings LLC reduced its stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 22.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,723,239 shares of the company's stock after selling 506,943 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 1.62% of MaxCyte worth $3,757,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>切維切斯信託控股公司在最近向證券交易委員會提交的 13F 文件中表示，在第二季度將其在 MaxCyte, Inc.（納斯達克代碼：MXCT - 免費報告）中的股份減少了 22.7%。該機構投資者在此期間出售了 506,943 股後，持有 1,723,239 股該公司的股票。切維切斯信託控股公司在最近的報告期末持有約 1.62% 的 MaxCyte 股份，價值 375.7 萬美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in the stock. Mudita Advisors LLP increased its holdings in MaxCyte by 3.3% in the 1st quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock valued at $9,087,000 after purchasing an additional 105,034 shares in the last quarter. Gagnon Securities LLC increased its holdings in MaxCyte by 431.3% in the 1st quarter. Gagnon Securities LLC now owns 1,048,318 shares of the company's stock valued at $2,862,000 after purchasing an additional 850,992 shares in the last quarter. Royce &amp; Associates LP increased its holdings in MaxCyte by 30.1% in the 1st quarter. Royce &amp; Associates LP now owns 1,040,873 shares of the company's stock valued at $2,842,000 after purchasing an additional 241,000 shares in the last quarter. Gagnon Advisors LLC acquired a new stake in MaxCyte in the 1st quarter valued at $2,550,000. Finally, Rice Hall James &amp; Associates LLC increased its holdings in MaxCyte by 72.2% in the 1st quarter. Rice Hall James &amp; Associates LLC now owns 454,365 shares of the company's stock valued at $1,240,000 after purchasing an additional 190,532 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也增加或減少了對該股票的持股。Mudita Advisors LLP 在第一季度將其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 現在持有 3,328,441 股該公司的股票，價值 908.7 萬美元，此前在上個季度購買了 105,034 股。Gagnon Securities LLC 在第一季度將其在 MaxCyte 的持股增加了 431.3%。Gagnon Securities LLC 現在持有 1,048,318 股該公司的股票，價值 286.2 萬美元，此前在上個季度購買了 850,992 股。Royce &amp; Associates LP 在第一季度將其在 MaxCyte 的持股增加了 30.1%。Royce &amp; Associates LP 現在持有 1,040,873 股該公司的股票，價值 284.2 萬美元，此前在上個季度購買了 241,000 股。Gagnon Advisors LLC 在第一季度獲得了 MaxCyte 的新股份，價值 255 萬美元。最後，Rice Hall James &amp; Associates LLC 在第一季度將其在 MaxCyte 的持股增加了 72.2%。Rice Hall James &amp; Associates LLC 現在持有 454,365 股該公司的股票，價值 124 萬美元，此前在上個季度購買了 190,532 股。目前 68.81% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, CFO Douglas J. Swirsky purchased 50,000 shares of the company's stock in a transaction on Wednesday, August 13th. The shares were bought at an average price of $1.29 per share, for a total transaction of $64,500.00. Following the completion of the purchase, the chief financial officer owned 161,811 shares of the company's stock, valued at $208,736.19. This trade represents a 44.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Stanley C. Erck purchased 100,000 shares of the company's stock in a transaction on Wednesday, August 13th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $137,000.00. Following the purchase, the director directly owned 398,328 shares of the company's stock, valued at $545,709.36. This trade represents a 33.52% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 355,000 shares of company stock valued at $479,950 in the last ninety days. Insiders own 3.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席財務官 Douglas J. Swirsky 在 8 月 13 日星期三購買了 50,000 股該公司的股票。每股平均購買價格為 1.29 美元，總交易額為 64,500.00 美元。購買完成後，首席財務官持有 161,811 股該公司的股票，價值 208,736.19 美元。這筆交易代表了他們持股的 44.72% 的增長。該購買在向證券交易委員會的文件中披露，相關信息可通過 SEC 網站獲取。此外，董事 Stanley C. Erck 在 8 月 13 日星期三購買了 100,000 股該公司的股票。該股票的平均購買價格為 1.37 美元，總交易額為 137,000.00 美元。購買後，該董事直接持有 398,328 股該公司的股票，價值 545,709.36 美元。這筆交易代表了他們持股的 33.52% 的增長。該購買的披露信息可以在這裏找到。內部人士在過去九十天內購買了 355,000 股公司股票，價值 479,950 美元。內部人士持有該公司 3.30% 的股票。</p>
</div><h2>MaxCyte Stock Performance</h2>
<div class="lb-trans"><h2>MaxCyte 股票表現</h2>
</div><p>NASDAQ:MXCT opened at $1.75 on Tuesday. The stock has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.02. MaxCyte, Inc. has a one year low of $1.26 and a one year high of $5.20. The company has a market capitalization of $186.56 million, a price-to-earnings ratio of -4.07 and a beta of 1.23.</p>
<div class="lb-trans"><p>納斯達克：MXCT 在星期二開盤價為 1.75 美元。該股票的 50 日簡單移動平均為 1.51 美元，200 日簡單移動平均為 2.02 美元。MaxCyte, Inc.的年低為 1.26 美元，年高為 5.20 美元。該公司的市值為 1.8656 億美元，市盈率為-4.07，貝塔值為 1.23。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%.The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $9.57 million. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MaxCyte（納斯達克：MXCT - 獲取免費報告）最近在 8 月 6 日星期三發佈了其財報。該公司報告季度每股收益（EPS）為（0.12 美元），低於分析師一致預期的（0.10 美元）2 美分。MaxCyte 的股本回報率為-22.12%，淨利潤率為-125.22%。該季度的營業收入為 851 萬美元，而一致預期為 957 萬美元。平均而言，股票研究分析師預測 MaxCyte, Inc.在當前財年將發佈-0.42 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several analysts recently issued reports on the company. Wall Street Zen downgraded MaxCyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, August 9th. Stephens began coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an &#34;overweight&#34; rating and a $6.00 price objective for the company. BTIG Research reissued a &#34;neutral&#34; rating on shares of MaxCyte in a research report on Monday, August 11th. William Blair cut shares of MaxCyte from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday, August 7th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of MaxCyte in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>幾位分析師最近對該公司發佈了報告。華爾街 Zen 在 8 月 9 日星期六將 MaxCyte 的評級從 “持有” 下調至 “賣出”。Stephens 在 7 月 22 日星期二的研究報告中開始覆蓋 MaxCyte 的股票。他們給予了 “增持” 評級，並設定了 6.00 美元的目標價。BTIG Research 在 8 月 11 日星期一的研究報告中重新發布了 MaxCyte 的 “中性” 評級。William Blair 在 8 月 7 日星期四的研究報告中將 MaxCyte 的股票評級從 “跑贏大盤” 下調至 “市場表現”。最後，Weiss Ratings 在 10 月 14 日星期二的研究報告中重新發布了 MaxCyte 的 “賣出（d-）” 評級。兩位研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 7.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on MaxCyte</strong></p>
<div class="lb-trans"><p><strong>查看我們對 MaxCyte 的最新股票分析</strong></p>
</div><h2>About MaxCyte</h2>
<div class="lb-trans"><h2>關於 MaxCyte</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.</p>
<div class="lb-trans"><p>MaxCyte, Inc.是一家生命科學公司，在美國和國際上發現、開發和商業化下一代細胞療法。其產品包括 ExPERT ATx，一種用於小到中型規模轉染的靜態電穿孔儀；ExPERT STx，一種用於蛋白質生產和藥物開發的流動電穿孔儀，以及用於細胞基礎檢測的治療靶標表達；ExPERT GTx，一種用於治療應用的大規模轉染的流動電穿孔儀；以及 ExPERT VLx，用於非常大體積的細胞工程。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦閲讀</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>3 High-Yield Banks for Investors to Buy on the Dip</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票勝過 MaxCyte</li>
<li>投資優先股與普通股的比較</li>
<li>路易威登財報顯示奢侈品牛市尚未結束</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>3 家高收益銀行供投資者在下跌時購買</li>
<li>一些最佳的大盤股有哪些？</li>
<li>5 只意外受益於未來機器人熱潮的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MXCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MaxCyte 嗎？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MaxCyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 MaxCyte 並不在名單上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MaxCyte 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Chevy Chase Trust Holdings LLC 出售了 MaxCyte, Inc. $MXCT 的股票